Clinical Trial Update: Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Erlotinib with Modified FOLFOX6 and Bevacizumab as first-line therapy for metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)
• Modified FOLFOX6 regimen

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Colorectal Cancer | Phase 1 | Status: COMPLETED